Bard Financial Services Inc. Sells 25 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bard Financial Services Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 230 shares of the biopharmaceutical company’s stock after selling 25 shares during the period. Bard Financial Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $242,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. SteelPeak Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 692 shares in the last quarter. Atria Investments Inc raised its holdings in Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares during the period. Tri Locum Partners LP raised its stake in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Nordea Investment Management AB grew its holdings in Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after buying an additional 5,495 shares in the last quarter. Finally, Tidal Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after acquiring an additional 711 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,033 shares of company stock worth $9,399,345. Corporate insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on REGN shares. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 25th. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Wells Fargo & Company reiterated an “overweight” rating and issued a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 23rd. Finally, Royal Bank of Canada lifted their target price on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an “outperform” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,119.00.

Regeneron Pharmaceuticals Stock Down 0.2 %

Regeneron Pharmaceuticals stock traded down $1.77 during midday trading on Friday, reaching $1,012.82. The company’s stock had a trading volume of 1,071,799 shares, compared to its average volume of 653,199. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a market cap of $111.65 billion, a P/E ratio of 29.92, a P/E/G ratio of 3.55 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The business has a 50-day simple moving average of $1,125.65 and a 200-day simple moving average of $1,037.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the firm posted $8.79 EPS. The company’s revenue was up 12.3% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.